INDGN Share Price Performance
₹440.65
-111.40 (-20.18%)
26.9% undervalued intrinsic discount
₹603.00
Fair Value
Price ₹440.65
AnalystConsensusTarget ₹603.00
max_profit ₹808.94
Fair Value₹603.00
Share Pricen/a
Indegene Limited Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
INDGN Community Narratives
AN
Fair Value ₹603 26.9% undervalued intrinsic discount
Digital Transformation And AI Adoption Will Expand Pharma Market
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
MA
Fair Value ₹808.94 45.5% undervalued intrinsic discount
Indegene deep undervalued stock
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Indegene deep undervalued stock
At ₹429–430 levels (near 52-week low), Indegene offers excellent risk-reward for 12–24 month horizon. Explosive long-term growth (35% sales CAGR, 68% profit CAGR), first $100M quarter, near-zero debt, and powerful AI/GenAI positioning in the high-growth life-sciences sector make this a high-quality compounder.Read more
74
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
MA
₹808.94
45.5% undervalued intrinsic discount
Fair Value
Revenue
15.98% p.a.
Profit Margin
13.46%
Future PE
40x
Price in 2031
₹1.54k
Digital Transformation And AI Adoption Will Expand Pharma Market
Key Takeaways AI-driven digital solutions and deeper multi-year client relationships are expanding Indegene's market presence, improving revenue growth and operational efficiencies in pharma services. Strategic reinvestment and targeted acquisitions are shifting revenues toward higher-margin, technology-led offerings and expanding capabilities across new verticals and geographies.Read more
88
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
₹603
26.9% undervalued intrinsic discount
Fair Value
Revenue
17.29% p.a.
Profit Margin
13.54%
Future PE
29.79x
Price in 2029
₹887.18
Trending Discussion
Recently Updated Narratives
MA
Indegene deep undervalued stock
Fair Value: ₹808.94 45.5% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Fair Value: ₹603 26.9% undervalued intrinsic discount
10 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Indegene Limited Key Details
About INDGN
- Founded
- 1998
- Employees
- 4158
- CEO
- WebsiteView website
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
